SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Majem, Margarita
- dc.contributor.author García-Martínez, E.
- dc.contributor.author Martínez-García, Maria
- dc.contributor.author Muñoz Couselo, Eva
- dc.contributor.author Rodríguez-Abreu, D.
- dc.contributor.author Alvarez, R.
- dc.contributor.author Arance, Ana
- dc.contributor.author Berrocal, A.
- dc.contributor.author de la Cruz-Merino, L.
- dc.contributor.author López-Martín, J.A.
- dc.date.accessioned 2021-04-16T07:30:21Z
- dc.date.available 2021-04-16T07:30:21Z
- dc.date.issued 2020
- dc.description.abstract The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. These are pathophysiologically unique toxicities, compared with those from other anticancer therapies. In addition, the spectrum of the target organs is very broad. Immune-inflammatory adverse events can be life threatening. Prompt diagnosis and pharmacological intervention are instrumental to avoid progression to severe manifestations. Consequently, clinicians require new skills to successfully diagnose and manage these events. These SEOM guidelines have been developed with the consensus of ten medical oncologists. Relevant studies published in peer-review journals were used for the guideline elaboration. The Infectious Diseases Society of America grading system was used to assign levels of evidence and grades of recommendation.
- dc.format.mimetype application/pdf
- dc.identifier.citation Majem M, García-Martínez E, Martínez M, Muñoz-Couselo E, Rodríguez-Abreu D, Alvarez R, et al. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). Clin Transl Oncol. 2020 Feb; 22(2):213-22. DOI: 10.1007/s12094-019-02273-x
- dc.identifier.doi http://dx.doi.org/10.1007/s12094-019-02273-x
- dc.identifier.issn 1699-048X
- dc.identifier.uri http://hdl.handle.net/10230/47133
- dc.language.iso eng
- dc.publisher SpringerOpen
- dc.rights Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Immunotherapy
- dc.subject.keyword Toxicity
- dc.subject.keyword irAEs
- dc.title SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion